Search the Newsreel

Vanda Pharma's new motion sickness drug NEREUS™ sponsors No. 47 IndyCar, marking a 47-year treatment milestone

Vanda Pharmaceuticals announced that its new FDA-approved motion sickness drug, NEREUS™ (tradipitant), will sponsor the No. 47 IndyCar, highlighting it as the first new prescription treatment for motion-induced vomiting in 47 years. This partnership underscores the drug's significance in offering a modern option for …

47 years since the last new motion-sickness treatment, NEREUS will sponsor IndyCar

Vanda Pharmaceuticals announced that its NEREUS™ (tradipitant) medication, the first new prescription treatment for motion-induced vomiting in 47 years, will sponsor the No. 47 entry in the NTT IndyCar Series. This partnership with Rahal Letterman Lanigan Racing highlights NEREUS's breakthrough innovation and will feature …

IndyCar News: Vanda Pharmaceuticals Sponsor Schumacher for Four Races

Vanda Pharmaceuticals, a biopharmaceutical company, announced its sponsorship of Mick Schumacher's No. 47 NTT INDYCAR SERIES entry for four races in 2026. The sponsorship will feature Vanda's NEREUS™ product, an oral neurokinin-1 (NK-1) receptor antagonist for motion-induced vomiting, on Schumacher's Honda. This marks Vanda's …

Vanda Pharmaceuticals (VNDA) Receives FDA Rare Pediatric Disease Designation

VNDA Forecast — Price Target — Prediction for 2027

How The Vanda Pharmaceuticals (VNDA) Investment Story Is Shifting With BYSANTI And Nereus

Vanda: A Long-Term Pharma Growth Idea, Despite Q1 Earnings Miss (NASDAQ:VNDA)

Earnings call transcript: Vanda Pharmaceuticals Q1 2026 misses EPS forecast, stock drops

VNDA Projected Revenue Forecast for 2026 at $258.2 Million

Earnings call transcript: Vanda Pharmaceuticals misses Q1 2026 forecasts, stock rises

Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates

Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results

Vanda Pharmaceuticals (VNDA) Is Up 13.3% After Rare FDA Hearing Granted on HETLIOZ Jet Lag Bid

FDA Approval Pushes Vanda Pharmaceuticals Shares Higher

Vanda Pharmaceuticals (VNDA) Stock Falls on Q4 2025 Earnings

VNDA Price Today: Vanda Pharmaceuticals Inc. Stock Price, Quote & Chart | MEXC

Vanda Pharmaceuticals: Could Now Be A Good Time To Invest?